blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3062809

EP3062809 - A CXCR4 PEPTIDE INHIBITOR FOR USE IN TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION [Right-click to bookmark this link]
Former [2016/36]METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION
[2019/42]
StatusNo opposition filed within time limit
Status updated on  14.05.2021
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  10.02.2020
FormerExamination is in progress
Status updated on  02.02.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Biokine Therapeutics Ltd.
Building 13a
Einstein Street, Science Park
Kiryat Weizmann
7403617 Nes Ziona / IL
For all designated states
BioLineRx Ltd.
2 HaMaayan Street
7177871 Modiin / IL
[2018/07]
Former [2017/45]For all designated states
Biokine Therapeutics Ltd.
Building 13a
Einstein Street
Science Park Kiryat Weizmann
7403617 Nes Ziona / IL
For all designated states
Biolinerx Ltd.
2 HaMaayan Street
7177871 Modiin / IL
Former [2016/36]For all designated states
Biokine Therapeutics Ltd.
Building 13a
Einstein Street
Science Park Kiryat Weizmann
7403617 Nes Ziona / IL
For all designated states
Bioline RX Ltd
19 Hartum Street
Har Hotzvim
P.O. Box 45158
91450 Jerusalem / IL
Inventor(s)01 / PELED, Amnon
55 Nahmani Street
6777634 Tel-Aviv / IL
02 / ABRAHAM, Michal
43 HaYasmin Street
P.O. Box 1228
9077243 Mevasseret Zion / IL
 [2016/36]
Representative(s)Inspicos P/S
Agern Allé 24
2970 Hørsholm / DK
[N/P]
Former [2016/36]Inspicos P/S
Kogle Allé 2
2970 Hørsholm / DK
Application number, filing date14802211.430.10.2014
[2016/36]
WO2014IL50939
Priority number, dateUS201361897921P31.10.2013         Original published format: US 201361897921 P
US201461945302P27.02.2014         Original published format: US 201461945302 P
[2016/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015063768
Date:07.05.2015
Language:EN
[2015/18]
Type: A1 Application with search report 
No.:EP3062809
Date:07.09.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 07.05.2015 takes the place of the publication of the European patent application.
[2016/36]
Type: B1 Patent specification 
No.:EP3062809
Date:08.07.2020
Language:EN
[2020/28]
Search report(s)International search report - published on:EP07.05.2015
ClassificationIPC:A61K38/10, A61K31/5377, A61K31/7068, A61P35/00
[2020/03]
CPC:
A61K38/10 (EP,CN,US); A61K31/5377 (EP,CN,US); A61K31/7068 (EP,CN,US);
A61K45/06 (US); A61K9/0019 (CN,US); A61P35/00 (EP);
A61P35/02 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/5377, A61K2300/00 (CN);
A61K31/7068, A61K2300/00 (CN);
A61K38/10, A61K2300/00 (CN)
Former IPC [2016/36]A61K38/10, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/36]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:EIN CXCR4 PEPTIDE INHIBITOR ZUR BEHANDLUNG VON AKUTER MYELOISCHER LEUKÄMIE MIT EINER FLT3-MUTATION[2020/10]
English:A CXCR4 PEPTIDE INHIBITOR FOR USE IN TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION[2019/42]
French:UN INHIBITEUR PEPTIDIQUE DE CXCR4 POUR LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË AVEC MUTATION DE LA FLT3[2019/42]
Former [2016/36]VERFAHREN ZUR BEHANDLUNG VON AKUTER MYELOISCHER LEUKÄMIE MIT EINER FLT3-MUTATION
Former [2016/36]METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION
Former [2016/36]MÉTHODES DE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË AVEC MUTATION DE LA FLT3
Entry into regional phase31.05.2016National basic fee paid 
31.05.2016Designation fee(s) paid 
31.05.2016Examination fee paid 
Examination procedure18.04.2016Amendment by applicant (claims and/or description)
31.05.2016Examination requested  [2016/36]
05.02.2018Despatch of a communication from the examining division (Time limit: M08)
12.10.2018Reply to a communication from the examining division
11.02.2020Communication of intention to grant the patent
28.05.2020Fee for grant paid
28.05.2020Fee for publishing/printing paid
28.05.2020Receipt of the translation of the claim(s)
Opposition(s)09.04.2021No opposition filed within time limit [2021/24]
Fees paidRenewal fee
21.10.2016Renewal fee patent year 03
25.10.2017Renewal fee patent year 04
24.10.2018Renewal fee patent year 05
25.10.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.10.2014
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
TR08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IE30.10.2020
LU30.10.2020
BE31.10.2020
IS08.11.2020
PT09.11.2020
[2022/32]
Former [2022/27]HU30.10.2014
AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
MT08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
TR08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IE30.10.2020
LU30.10.2020
BE31.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/46]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IE30.10.2020
LU30.10.2020
BE31.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/36]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SI08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
LU30.10.2020
BE31.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/31]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
LU30.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/28]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/25]AL08.07.2020
AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/22]AT08.07.2020
CZ08.07.2020
DK08.07.2020
EE08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SM08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/21]AT08.07.2020
DK08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RS08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/10]AT08.07.2020
FI08.07.2020
HR08.07.2020
LT08.07.2020
LV08.07.2020
PL08.07.2020
RS08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
IS08.11.2020
PT09.11.2020
Former [2021/09]AT08.07.2020
FI08.07.2020
LT08.07.2020
BG08.10.2020
NO08.10.2020
GR09.10.2020
PT09.11.2020
Former [2021/08]FI08.07.2020
LT08.07.2020
BG08.10.2020
NO08.10.2020
PT09.11.2020
Former [2021/07]FI08.07.2020
LT08.07.2020
NO08.10.2020
Cited inInternational search[XYI]  - ZENG ZHIHONG ET AL, "Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, (20061201), vol. 5, no. 12, doi:10.1158/1535-7163, ISSN 1535-7163, pages 3113 - 3121, XP008139367 [X] 1-5,7,12,13,15,16 * abstract * * page 3118, column right, paragraph 2; figure 6 * * page 3120, column right, paragraph 2 * [Y] 8 [I] 1-7,9-16

DOI:   http://dx.doi.org/10.1158/1535-7163
 [XY]  - KATIA BEIDER ET AL, "CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 39, no. 3, doi:10.1016/J.EXPHEM.2010.11.010, ISSN 0301-472X, (20101130), pages 282 - 292, (20101205), XP028161350 [X] 3-5 * abstract * * figure 6 * [Y] 8

DOI:   http://dx.doi.org/10.1016/j.exphem.2010.11.010
 [A]  - JACOBI A ET AL, "Impact of CXCR4 inhibition on FLT3-ITDpositive human AML blasts", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 38, no. 3, doi:10.1016/J.EXPHEM.2009.12.003, ISSN 0301-472X, (20100301), pages 180 - 190, (20100218), XP026913582 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1016/j.exphem.2009.12.003
 [A]  - ZENG Z ET AL, "Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 113, no. 24, doi:10.1182/BLOOD-2008-05-158311, ISSN 0006-4971, (20090611), pages 6215 - 6224, (20081027), XP002716127 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1182/blood-2008-05-158311
 [A]  - QIN T ET AL, "Effect of Cytarabine and Decitabine in combination in human leukemic cell lines", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20070715), vol. 13, no. 14, ISSN 1078-0432, pages 4225 - 4232, XP002725241 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-06-2762
 [A]  - AMNON PELED ET AL, "Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia", THERANOSTICS, (20130101), vol. 3, no. 1, doi:10.7150/thno.5150, ISSN 1838-7640, pages 34 - 39, XP055164251 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.7150/thno.5150
 [XP]  - Yaron Pereg ET AL, "BL-8040, a CXCR4 antagonist, synergizes with the FLT3 inhibitor AC220 inducing apoptosis and reducing minimal residual disease to prolong survival of AML diseased mice", SOHO Annual Meeting Proceedings, (20140917), page 203, URL: http://soho2014.com/wp-content/uploads/203.pdf, (20150122), XP055164272 [XP] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1016/j.clml.2015.04.021
by applicantUS3791932
 US3839153
 US3850752
 US3850578
 US3853987
 US3867517
 US3879262
 US3901654
 US3935074
 US3984533
 US3996345
 US4034074
 US4098876
 US4666828
 US4683202
 US4801531
 US4879219
 US5011771
 US5192659
 US5272057
 US5281521
 WO0009152
 WO0220561
 US2002156034
 WO2004020462
 WO2004024178
 WO2004087068
 WO2007022523
    - ESTEY ET AL., LANCET, (2006), vol. 368, pages 1894 - 1907
    - LEVIS; SMALL, LEUKEMIA, (2003), vol. 17, pages 1738 - 1752
    - FATHI; CHEN, AM. J. BLOOD RES., (2011), vol. 1, pages 17 - 18
    - TAMAMURA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1998), vol. 253, no. 3, pages 877 - 882
    - TAINAMURA ET AL., ORG. BIOMOL. CHEM., (2003), vol. 1, pages 3663 - 3669
    - BEIDER ET AL., EXP. HEMATOL., (2011), vol. 39, pages 282 - 92
    - MURPHY ET AL., J MOL. DIAGN., (2003), vol. 5, pages 96 - 102
    - MARKOVIC ET AL., J. BIOCHEM. CELL BIOL., (2005), vol. 37, no. 6, pages 1168 - 72
    - NAKAO ET AL., LEUKEMIA, (1996), vol. 10, no. 12, pages 1911 - 8
    - HUANG ET AL., JOURNAL OF SURGICAL RESEARCH, (2009), vol. 155, pages 231 - 236
    - TAN NC; YU P; KWON Y-U; KODADEK T, "High-throughput evaluation of relative cell permeability between peptoids and peptides", BIOORG MED CHEM., (2008), vol. 16, doi:doi:10.1016/j.bmc.2008.04.074, pages 5853 - 61, XP022700315

DOI:   http://dx.doi.org/10.1016/j.bmc.2008.04.074
    - KWON Y-U; KODADEK T, "Quantitative evaluation of the relative cell permeability of peptoids and peptides", J AM CHEM SOC., (2007), vol. 129, page 1508
    - MILLER S; SIMON R; NG S; ZUCKERMANN R; KERR J; MOOS W, "Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers", DRUG DEV RES., (1995), vol. 35, pages 20 - 32
    - YOSHIKAWA Y; KOBAYASHI K; OISHI S; FUJII N; FURUYA T, "Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions", BIOORG MED CHEM LETT., (2012), vol. 22, doi:doi:10.1016/j.bmcl.2012.01.134, pages 2146 - 50, XP028402827

DOI:   http://dx.doi.org/10.1016/j.bmcl.2012.01.134
    - JAÄHNICHEN S; BLANCHETOT C; MAUSSANG D; GONZALEZ-PAJUELO M; CHOW KY; BOSCH L; DE VRIEZE S; SERRUYS B; ULRICHTS H; VANDEVELDE W, "CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells", PROC NATL ACAD SCI USA., (2010), vol. 107, doi:doi:10.1073/PNAS.1012865107, pages 20565 - 70, XP002611004

DOI:   http://dx.doi.org/10.1073/PNAS.1012865107
    - "Principles of Cancer Therapy", SLAPAK; KUFE, Harrison's Principles of Internal medicine
    - The Cancer Chemotherapeutic Handbook, MOSBY-YEAR HANDBOOK
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO.
    - SEKIDO ET AL., CANCER GENET CYTOGENET, (2002), vol. 137, no. 1, pages 33 - 42
    - Current Protocols in Molecular Biology, (1994), vol. I-III
    - WATSON ET AL., Recombinant DNA, SCIENTIFIC AMERICAN BOOKS
    - Genome Analysis: A Laboratory Manual Series, COLD SPRING HARBOR LABORATORY PRESS, (1998), vol. 4
    - Cell Biology: A Laboratory Handbook, (1994), vol. I-III
    - Current Protocols in Immunology, (1994), vol. I-III
    - Methods in Enzymology, ACADEMIC PRESS, vol. 1-317
    - BEIDER; BEGIN, EXP HEMATOL, (2011), vol. 39, pages 282 - 92
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.